Sol-gel Technologies vs Verrica Pharmaceuticals
Verrica Pharmaceuticals is the larger business, with $35.6m of revenue in fiscal 2025 against $19.4m for Sol-gel Technologies (1.8 times as much). Verrica Pharmaceuticals grew faster (370.2% against 68.0%). Sol-gel Technologies kept more of each dollar of sales as profit: a net margin of -31.6% against -50.3%. Sol-gel Technologies carries less debt relative to equity (0.0% against 0.0%).
| Latest fiscal year | Sol-gel TechnologiesSLGL, 2025 | Verrica PharmaceuticalsVRCA, 2025 |
|---|---|---|
| Revenue | $19.4m | $35.6m |
| Revenue growth | 68.0% | 370.2% |
| Net income | −$6.1m | −$17.9m |
| Operating margin | -38.9% | -34.2% |
| Net margin | -31.6% | -50.3% |
| Return on equity | -23.7% | — |
| Free cash flow | $275,000 | −$17.6m |
| Cash | $11.0m | $30.1m |
| Total debt | $0 | $0 |
| Debt to equity | 0.0% | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | — | 76 |
| Market value | $184m | $57.5m |
| Price vs our value range | — | — |
| Moat score | — | 8 (Weak) |
| Insider trades, 12 months | 49 buys, 0 sales | 12 buys, 0 sales |